Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of S6G5T-3 and S6G5T-1 in Acne Vulgaris
NCT02661958Phase 2Completed
- Sponsor
- Sol-Gel Technologies
- Start
- May 2016
- Primary completion
- Oct 2017
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of benzoyl peroxide + tretinoin in acne vulgaris (6 arms), sponsored by Sol-Gel Technologies. Primary endpoints: Investigator's Global Assessment at 12 weeks and Absolute change in lesion count (inflammatory and non-inflammatory) at 12 weeks. Started May 2016; status: completed.
02
Drugs
benzoyl peroxide + tretinoin
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT02661958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02661958.